within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AL04_Remoxipride;

model Remoxipride
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.42,
    Cl = 2.7222222222222223e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0029,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.013333333333333334,
    Tlag = 0,
    Vdp = 0.0011,
    k12 = 2.5277777777777783e-05,
    k21 = 2.5277777777777783e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Remoxipride</td></tr><tr><td>ATC code:</td><td>N05AL04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.4</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Remoxipride is an atypical antipsychotic drug, primarily acting as a dopamine D2 receptor antagonist. It was used for the treatment of schizophrenia and related psychotic disorders, but has since been withdrawn from the market worldwide due to reports of aplastic anemia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AL04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Remoxipride;
